Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer

Clinical Breast Cancer
Denise A YardleyJohn D Hainsworth

Abstract

Inhibition of the platelet-derived growth factor receptor (PDGFR) might improve the efficacy of chemotherapy by lowering interstitial tumor pressure and allowing increased tumor penetration by cytotoxic agents. In this phase II trial, we added imatinib, a PDGFR inhibitor, to docetaxel in the first-line treatment of women with metastatic breast cancer (MBC). Women with MBC who had received a maximum of 1 previous chemotherapy regimen were eligible for this trial. Initially, patients received oral imatinib 600 mg daily and docetaxel 30 mg/m2 on days 1, 8, and 15 of a 28-day cycle. The imatinib dose was lowered from 600 mg to 400 mg daily because of toxicity (primarily gastrointestinal) observed in the first 15 patients. Patients were evaluated for response (Response Evaluation Criteria in Solid Tumors) after 8 weeks of therapy; treatment continued in responding/stable patients until tumor progression or unacceptable toxicity. The primary endpoint was the overall response rate. Thirty-seven patients entered this trial between May 2005 and March 2008. This regimen was relatively poorly tolerated, even after reduction of the imatinib dose, primarily because of gastrointestinal toxicity (nausea, vomiting, and diarrhea). Eight patient...Continue Reading

References

Dec 4, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael C HeinrichJonathan A Fletcher
Aug 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S E JonesP M Ravdin
Sep 7, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·David R SpigelUNKNOWN Minnie Pearl Cancer Research Network
Feb 15, 2008·Clinical Genitourinary Cancer·John D HainsworthF Anthony Greco

❮ Previous
Next ❯

Citations

Feb 26, 2011·Breast Cancer Research and Treatment·Roisin M ConnollyAntonio C Wolff
Jul 14, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N StarlingD Cunningham
Aug 18, 2012·Journal of Translational Medicine·Kiana KeyvanjahWilliam Carley
Sep 29, 2011·The Oncologist·Alberuni M ZamahMitchell P Rosen
Jun 25, 2014·The Journal of Clinical Investigation·Bin YuanRong Li
Jul 23, 2015·Genes·Mark R Pickard, Gwyn T Williams
Sep 6, 2011·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Anne S TsaoDavid J Stewart
Aug 30, 2011·Cancer Treatment Reviews·Javier Cortes, Henri Roché
Jan 22, 2011·Trends in Molecular Medicine·Andrea MorandiClare M Isacke
Apr 5, 2013·Molecular Nutrition & Food Research·Yinan HuaSreejayan Nair
Nov 19, 2015·International Journal of Molecular Sciences·Ewa MajJoanna Wietrzyk
Jan 1, 2011·Cancers·Yasuhiko KitadaiKei Shinagawa
Mar 22, 2012·Medicinal Research Reviews·Mohammed I El-GamalChang-Hyun Oh
Dec 3, 2016·The Journal of Biological Chemistry·Peter B AlexanderXiao-Fan Wang

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.